HAS Healthcare Advanced Synthesis Group Announces Strategic Investments in Biodelphis Therapeutics to Advance Development and Manufacturing of Antibody Protease Inhibitor Conjugates (APICs)
Lugano, Switzerland — May 4, 2026
HAS Healthcare Advanced Synthesis and Biodelphis Therapeutics today announced the signing of a strategic agreement to support the development and GMP manufacturing of Antibody Protease Inhibitor Conjugates, an emerging class of targeted therapeutics designed to selectively inhibit disease‑driving proteases.
This collaboration combines HAS Group long‑standing expertise in complex bioconjugation, process development, and clinical‑grade manufacturing with Biodelphis Therapeutics’ pioneering APIC platform, a novel drug modality engineered to deliver highly selective protease inhibition directly to diseased tissues.
Under the agreement, the two companies will work closely to accelerate the transition of first‑in‑class APIC candidates from early development into robust, scalable manufacturing processes. The partnership aims to strengthen the path toward clinical evaluation by integrating Biodelphis’ innovative therapeutic design with HAS/Cerbios’ proven capabilities in high‑quality bioconjugate production.
The announcement coincided with Swiss Biotech Day 2026 in Basel, where both companies will present. Biodelphis’ CEO, Aaron Petruzzella, will present the APIC platform and introduced the new partnership during his session at the event.
The session will take place at:
- Start‑up Track, Singapore Room — Tuesday at 15:30
The partnership marks a shared commitment to advancing next‑generation targeted therapies for patients with high unmet medical needs.
About HAS Healthcare Advanced Synthesis Group
HAS Healthcare Advanced Synthesis is part of the HAS Group, an integrated CDMO platform established in 2025 through the acquisition of Cerbios‑Pharma SA. Rooted in decades of Swiss precision and built on more than forty years of combined experience, the HAS Group brings together advanced chemical and biological expertise within a single, fully integrated organization.
With a robust portfolio of established APIs and pharmaceutical products, the Group delivers innovative solutions across highly specialized technologies, including Antibody‑Drug Conjugates (ADCs). This foundation reflects a long‑term vision driven by scientific excellence, quality, and strong family values.
We unite complementary capabilities in chemical and biological development, specializing in APIs, HPAPIs, anticancer compounds, linker‑payloads, and ADCs. Our end‑to‑end solutions guide projects from early‑phase development through commercial supply, leveraging multiple GMP‑certified sites across Switzerland. We combine scientific excellence with strategic agility to accelerate our partners’ success.
Whether advancing early‑stage research or scaling for global markets, HAS Group is your trusted partner to innovate, manufacture, and deliver.
About Biodelphis Therapeutics
Biodelphis Therapeutics is a Swiss biotech startup based in Lausanne that develops next‑generation protease‑targeting medicines using its proprietary Antibody‑Peptide Inhibitor Conjugate (APIC) technology. Spun out of EPFL, the company focuses on creating highly selective, cell‑targeted protease inhibitors designed to overcome the toxicity and specificity limitations of traditional small‑molecule approaches. Its APICore platform enables rapid design and optimization of potent peptide inhibitors that are activated only within intended cells, such as tumor cells, improving both efficacy and safety. Biodelphis is advancing a preclinical pipeline of first‑in‑class candidates targeting cathepsin proteases for oncology, bone health, and autoimmune diseases, with lead programs in lung adenocarcinoma and osteoporosis.
More info: BIODELPHIS Therapeutics
Press Office:
Giacomo Braglia
Tel: +41 (0) 91 873 94 00